A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center.
The study – the first trial to publish five-year results from SBRT treatment for prostate cancer – found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target. It is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue.
“The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,” said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study. “What we now have is a more potent and effective form of completely noninvasive treatment for prostate cancer, conveniently completed in five treatments.”
Conventional treatment options for early stage prostate cancer include:
- Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;
- Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room. Once implanted, the seeds release their radioactivity directly into the prostate gland; and
- External beam radiation, which involves 42 to 45 treatments administered over two or more months, five days a week.
“The current form of radiation is 44 treatments given over nine weeks. In contrast, the SBRT therapy we used allows the delivery of highly focused radiation in only five treatments, allowing patients to return to their normal lives more quickly,” said senior author Dr. Robert Timmerman, Director of the Annette Simmons Stereotactic Treatment Center at UT Southwestern, and Professor and Vice Chairman of the Department of Radiation Oncology. “SBRT is both more convenient and has increased potency.”
UT Southwestern served as the lead site for the multi-institutional clinical trial, which involved first-time prostate cancer patients diagnosed with stage I or stage II (low and intermediate risk) prostate cancer. A total of 91 patients were treated prospectively and followed for five years, with only one patient experiencing a recurrence of his cancer. The findings are published in the European Journal of Cancer.
Terry Martin of McKinney, Texas, – about an hour outside Dallas – said the fewer number of treatments was a compelling advantage when he was evaluating treatment options.
“I live 45 minutes away from UT Southwestern. The difference between being treated five times versus 44 times is enormous,” said Mr. Martin, a retired airline pilot. “I felt that I was back to normal just 10 days after finishing treatment.”
In addition to shorter treatment times, researchers found that side effects were not necessarily different compared to other forms of prostate cancer treatment. In the short term, the side effects of SBRT can include urinary issues (urgency, frequency and burning) and rectal irritation, which are often temporary and reverse within four weeks of treatment. Researchers found a small risk of longer-term urinary and rectal complications, which is also comparable to conventional treatments. Decrease in erectile function was seen in 25 percent of patients, fewer than with conventional radiation or surgery, said Dr. Hannan.
The Latest on: Stereotactic Body Radiation Therapy
via Google News
The Latest on: Stereotactic Body Radiation Therapy
- New guideline clarifies role of radiation therapy in pancreatic cancer treatmenton September 4, 2019 at 8:06 pm
"One thing this guideline offers that hasn't been available previously is context about the current status of ablative radiotherapy such as stereotactic body radiation therapy (SBRT) and where it ...
- Emerging Applications of Stereotactic Body Radiation Therapy for Head and Neck Canceron August 22, 2019 at 5:00 pm
Head and neck cancer is typically managed with surgery, radiation therapy, chemotherapy or various combinations of the above. In patients who develop recurrence after radiation therapy, treatment ...
- Emerging Application of Stereotactic Body Radiation Therapy for Gynecologic Malignancieson August 15, 2019 at 5:00 pm
Stereotactic body radiation therapy (SBRT) involves delivery of image-guided, ablative radiation doses to planning treatment volume(s) using sophisticated dosimetric planning and target localization.
- Stereotactic Body Radiation Therapy Market Size, Share, Opportunities, Development and Global Trend Analysis till 2025on August 11, 2019 at 6:57 pm
Aug 12, 2019 (The Expresswire) -- What's driving the Stereotactic Body Radiation Therapy Market Growth? Prominent Players: Siemens, Medical Systems, Inc., Elekta AB, IBA Worldwide 2019, BD, Isoray Inc ...
- When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapyon May 14, 2019 at 6:27 am
Historically, radiation therapy has played a limited role in the management of renal cell carcinoma because early studies showed that it had no benefit in the neoadjuvant or adjuvant settings. Thus, ...
- Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Canceron April 20, 2019 at 9:17 pm
This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer ...
- Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Canceron April 6, 2019 at 4:41 pm
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without stereotactic body radiation therapy works in treating patients with stage IV non-small cell lung ...
- High-dose stereotactic body radiotherapy well-tolerated by patients with centrally located lung tumorson April 5, 2019 at 10:38 am
Stereotactic Body Radiotherapy (SBRT), a high-dose ... the research of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic ...
- W.P. Holman Clinic commences stereotactic body radiation therapy serviceon February 16, 2019 at 10:30 pm
The delivery of state-of-the-art cancer treatment for patients in the state's North was at the core of Dr William Prout Holman's vision when he came to Tasmania in 1925. Now, almost a century later, a ...
- Stereotactic body radiotherapy effective in treating men with low- or intermediate-risk prostate canceron February 10, 2019 at 11:45 pm
This type of radiation, known as stereotactic body radiotherapy, is a form of external beam radiation therapy and reduces the duration of treatment from 45 days to four to five days. The approach has ...
via Bing News